24 citations
,
June 2013 in “Expert opinion on pharmacotherapy” Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
5 citations
,
February 1997 in “Bioorganic & Medicinal Chemistry” New compounds were made that effectively block a specific enzyme related to androgen conditions.
January 2026 in “Elsevier eBooks”
35 citations
,
October 2004 in “Biology of Reproduction” PNU157706 reduced rat sperm movement and fertility without affecting offspring health.
March 2014 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Dutasteride 0.5mg was found to be more effective than finasteride 1mg in treating male pattern hair loss, with similar side effects.
January 2026 in “Journal of Dermatological Treatment” Oral finasteride may cause more sexual side effects than expected, possibly due to negative publicity and reporting bias.
October 2006 in “Urology” Combination therapy with Finasteride is more effective than alpha-blocker alone for BPH symptoms in small prostate volume.
1 citations
,
December 2012 in “I P Pavlov Russian Medical Biological Herald” Finasteride increases P-glycoprotein activity in the liver and kidney.
Tamsulosin and finasteride together effectively slow down and prevent BPH progression.
September 2004 in “Urology” Dutasteride may help prevent prostate cancer, but more research is needed.
2 citations
,
January 2011 in “Clinical medicine insights” Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
3 citations
,
March 2005 in “The Journal of urology/The journal of urology” Dutasteride may help shrink prostate cancer tumors.
June 2025 in “Journal of Cosmetic Dermatology” Dutasteride 0.5 mg/day is the most effective treatment for male pattern hair loss.
November 2005 in “The Journal of Urology” Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.
3 citations
,
January 2010 in “Yearbook of Urology” January 2010 in “Yearbook of Urology”
20 citations
,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.
18 citations
,
June 2017 in “Journal of the neurological sciences” Using 5 alpha reductase inhibitors may increase dementia risk in the first two years.
April 2009 in “Journal of Pain” Finasteride reduces pain in male rats and works better with testosterone.
1 citations
,
July 2012 in “Der Urologe” Finasteride effectively reduces prostate size and symptoms in most BPH patients.
1 citations
,
October 2023 in “Journal of the Endocrine Society” Finasteride may worsen blood sugar control in diabetic patients.
October 2021 in “European urology open science” 2 citations
,
April 2024 in “Urology Annals” Taking dutasteride every other day works as well as daily and better preserves sexual function.
March 2019 in “European Urology Supplements” Some common medications like metformin, insulin, and ACE inhibitors can lower PSA levels, while statins don't, and low dose finasteride significantly reduces PSA.
11 citations
,
March 2019 in “Journal of The American Academy of Dermatology” Some men taking finasteride for hair loss may experience sexual problems like erectile dysfunction and decreased sex drive, which can persist even after stopping the medication.
Evidence-based urology improved treatment and quality of life for conditions like BPH by shifting from surgery to effective medications like finasteride and dutasteride.
January 2014 in “Hebei yixue” Combining tamsulosin and finasteride effectively improves urinary symptoms in elderly BPH patients.
1 citations
,
April 2009 in “Cochrane Database of Systematic Reviews” Finasteride effectively reduces symptoms of male chronic pelvic pain syndrome with few side effects.
May 2024 in “The journal of sexual medicine” Finasteride treatment may cause erectile dysfunction, but stopping it reverses these effects.
30 citations
,
June 2010 in “Endocrine Related Cancer” SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.